Mumbai: PIL against antibiotics’ sale without prescription

MUMBAI: A lawyer has filed a PIL in the Bombay HC against the Union and state governments, Central Drugs Standard Control Organization (CDSCO) and drug regulator to prevent the rampant sale of high-potency antibiotics without prescription, and often over-the-counter (OTC). India is the largest consumer of antibiotics.

The petition is a result of a survey, conducted across 500 pharmacies by an NGO, which showed that antibiotics under schedule H and H1 were easily available among other OTC products. Lawyer Bharat S Kothari, in the PIL, listed concerns such as serious drug resistances and infectious diseases.

Kothari says “over 118 different formulations of fixed dose combinations were being sold in India; in UK and US, only five are sold. Of these 118, 64% were not approved by CDSCO, even though the sale of unapproved new drugs is illegal in India.”

  • Related Posts

    Commissioner FDA reviews enforcement measures

    Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices